Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight

The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.

11/10/2026, 1:00 PM • GlobeNewswire

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

Gilead Sciences stock has surged 38% year-to-date, hitting all-time highs and outperforming the S&P 500. The pharmaceutical company's growth has improved significantly with strong results across HIV, liver disease, and oncology segments, while Veklury revenue declined post-COVID. Trading at a forward P/E of 17 with a 1.92% dividend yield, analysts suggest the stock remains attractively valued despite its recent gains.

11/10/2026, 5:49 AM • The Motley Fool

Compugen (CGEN) Q3 2026 Earnings Call Transcript

Compugen reported Q3 2026 results with revenue of $3.8 million and net loss of $5.8 million. The company completed enrollment in its MAIA-Ovarian trial for COM701 with data expected by end of Q1 2027. Partnered programs with AstraZeneca (rilvegostomig) and Gilead (GS-0321) continue advancing, with rilvegostomig in 12 Phase III trials. The company introduced UnigenX, expanding its discovery platform into tumor-associated antigens for T-cell engagers. Cash runway extends into 2029 with $117.5 million in cash and equivalents.

11/09/2026, 11:53 AM • The Motley Fool

Marengo Presents Interim Phase 2 STARt-002 Results for First-in-Class Selective T-Cell Agonist Invikafusp Alfa Plus Sacituzumab Govitecan Across Two Metastatic Breast Cancer Cohorts in Oral Presentation at SITC 2026

Marengo Therapeutics announced interim Phase 1b/2 results from the STARt-002 trial combining invikafusp alfa, a first-in-class selective T-cell agonist, with sacituzumab govitecan for metastatic breast cancer. The combination showed 71% reduction in target lesions, confirmed complete responses in both triple-negative and HR-positive/HER2-negative cohorts, and 74% disease control overall with a manageable safety profile.

11/09/2026, 7:00 AM • GlobeNewswire

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.

11/08/2026, 4:32 PM • The Motley Fool

Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors

The iShares U.S. Pharmaceuticals ETF (IHE) offers lower costs, higher dividend yield (1.4% vs 0.2%), and better 5-year returns (79% vs 38%) compared to the iShares Biotechnology ETF (IBB). IHE focuses on 53 established drugmakers with lower volatility, while IBB provides broader exposure to 243 biotech firms with higher risk. IHE may be preferable for income-focused investors, though IBB suits those seeking broader biotech sector exposure.

11/07/2026, 11:15 AM • The Motley Fool

The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?

Invesco Pharmaceuticals ETF (PJP) delivers higher returns (32.8% over one year, 10.7% CAGR since 2021) with concentrated U.S. pharma exposure but higher fees (0.58%), while iShares Global Healthcare ETF (IXJ) offers broader global diversification across 109 holdings, lower costs (0.38%), and higher dividend yield (1.3%), making it suitable for cost-conscious investors seeking diversified healthcare exposure.

11/07/2026, 9:15 AM • The Motley Fool

Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.

Gilead Sciences increased its quarterly dividend by 3.8% to $0.82, marking the 11th consecutive year of dividend increases. The company's strong HIV franchise generated 18% higher sales year-over-year, while its oncology expansion shows promise with Trodelvy reporting 42% sales growth. With a low payout ratio of 29.8%, Gilead has ample room to sustain dividend growth and fund $32 billion in research projects through 2030.

11/05/2026, 5:45 AM • The Motley Fool

1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November

Gilead Sciences is recommended as a strong dividend-paying biotech stock for November. The company delivered solid Q3 2026 results with 7% revenue growth to $8.3 billion, driven by strong HIV product sales (up 18% YoY) and liver disease portfolio performance. Recent FDA approvals including Bixlenvo and Hepcludex, combined with an expanding oncology pipeline, should support future growth. Trading at a reasonable 16.8x forward earnings with a 2% dividend yield and 74.5% payout increase over the past decade, Gilead appears well-positioned for long-term investors.

11/01/2026, 3:42 PM • The Motley Fool

Breakfast News: Brace for an AI Optics Shake-up

Marvell is reportedly in advanced talks to acquire Lumentum to control AI optics supply, a critical bottleneck in AI infrastructure. Alphabet slumped 10% despite strong cloud growth due to massive capital expenditures and negative free cash flow. Several earnings reports showed mixed results: Fortinet fell 25% on weak guidance, ServiceNow dropped 19% due to AI deployment costs, while Microsoft, Sterling Infrastructure, and Chipotle posted gains. DoorDash may acquire Instacart to compete in grocery delivery dominated by Instacart's 68% market share.

10/29/2026, 7:30 AM • The Motley Fool

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

Kymera Therapeutics reported Q3 2026 financial results with positive Phase 1 data for KT-579 (IRF5 degrader) showing deep, sustained target degradation and favorable safety profile. The company is advancing KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, with AD topline data expected by year-end 2026. Kymera maintains strong financial position with $1.6 billion in cash providing runway into 2029.

10/29/2026, 7:00 AM • GlobeNewswire

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.

10/27/2026, 10:50 AM • The Motley Fool

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?

VanEck Biotech ETF (BBH) offers lower costs (0.35% expense ratio) and concentrated exposure to 25 large-cap biotech leaders, outperforming Invesco Biotechnology & Genome ETF (PBE) over the past year. However, PBE delivers higher dividend income (1.3% yield) and slightly better five-year returns through a multifactor selection strategy. BBH is ideal for cost-conscious momentum investors, while PBE suits those seeking income and a diversified factor-driven approach.

10/27/2026, 10:43 AM • The Motley Fool

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy?

RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and IBB (iShares Biotechnology ETF) offer different approaches to healthcare investing. RSPH provides broader, equal-weighted healthcare exposure with lower volatility, higher dividend yield (0.6%), and a lower expense ratio (0.4%), making it suitable for risk-averse investors. IBB offers concentrated biotech exposure with stronger recent returns (35.5% vs 31.9%) but higher volatility and drawdown risk. The choice depends on investor risk tolerance and conviction in biotechnology's momentum.

10/26/2026, 9:53 AM • The Motley Fool

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH), which concentrates on 25 biotech companies with higher volatility, and Invesco S&P 500 Equal Weight Health Care ETF (RSPH), which diversifies across 61 healthcare companies. While BBH showed stronger 1-year returns (38.3% vs 25.7%), RSPH is recommended for long-term investors due to lower concentration risk, broader diversification, and higher dividend yield, despite slightly higher expense ratios.

10/25/2026, 5:20 AM • The Motley Fool